The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

But even in the US, where CAB-LA is marketed as Apretude, it has been hard for injectable PrEP to establish a significant market . There have now been about 11,000 prescriptions in the two years since ...

Several presentations at CROI 2024 addressed whether HIV is starting to develop resistance to the integrase inhibitor dolutegravir, one of the most widely used antiretrovirals in the world. In World ...

Viral load results are also important for other aspects of patient care, but there are no clear data showing the clinical relevance of results below 200 copies/ml. One exception is that a viral load ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

Using a computer model, researchers at University College London have found that there is no realistic chance in the UK of reaching the 'Ending AIDS' goal for 2030 that was first set by the United ...

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

By 2022, half of all patients eligible for this analysis were taking reduced-drug treatment. In people taking three-drug daily treatment in 2015, there was no change in the proportion who were virally ...